Last updated: 2026-09-09 19:19:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Precigen, Inc. (PGEN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $6.83, with a market capitalisation of $2.54B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.99 to $7.72. This page covers its latest market performance, valuation, price trends and company information.
$2.54B | |
$6.91 | |
$11.10 | |
$0.65 | |
$6.87 | |
1.69M | |
5.11M | |
-- | |
$7.72 | |
$2.99 | |
-- | |
-- |
Precigen, Inc. (PGEN) is currently trading at $6.83 as of 2026-09-09 19:02:29, down 0.66% ($0.04) from the previous close of $6.87
During today's regular trading session, PGEN has traded between $0.65 and $11.10, with a trading volume of 1.69M shares. The current price is near the middle of today's range.
Over the past seven days, Precigen, Inc. (PGEN) moved from $6.95 to $6.83, representing a decline of 1.80% ($0.13).
The stock traded between $6.60 and $7.27 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 2.78 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 81.2%
PGEN is currently trading at $6.83, placing it 81.2% of the way from its 52-week low of $2.99 to its 52-week high of $7.72. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 47 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Precigen, Inc. (PGEN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.